Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of TAK-881 and HyQvia in Healthy Adults
Sponsor: Takeda
Summary
The main aim of this study is to understand how the body absorbs, processes, and removes (known as pharmacokinetics or PK) TAK-881 and HyQvia, after they are given as a single injection under the skin in healthy adults. Study participants will receive a single dose of TAK-881 or HyQvia on Day 1. During the study, participants will need to stay at the clinic for 8 days followed by 8 ambulatory follow up visits till Day 85.
Official title: A Phase 1, Randomized, Open-Label, Pharmacokinetic Trial of TAK-881 and HyQvia in Healthy Adults
Key Details
Gender
All
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-03-24
Completion Date
2025-08-08
Last Updated
2026-06-11
Healthy Volunteers
Yes
Conditions
Interventions
TAK-881
Participants will receive SC infusion of TAK-881.
HyQvia
Participants will receive SC infusion of HyQvia.
SC Investigational Needle Sets
The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
SC Investigational Needle Sets
The single-use only SC needle set will be used to administer HyQvia to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
Locations (1)
Celerion
Tempe, Arizona, United States